Skip to main content
. 2020 Sep 4;12(9):846. doi: 10.3390/pharmaceutics12090846

Figure 9.

Figure 9

CYP450 metabolic pathways involved in the metabolism of erythromycin and midazolam and their respective affinities for the isoform are depicted. Mechanism-based inhibition at the CYP3A4 enzymatic level will be expected. Midazolam is the victim drug and erythromycin acts as the perpetrator drug.